Biotech Values

[EnergyFundies]

This is the quote from 3Q earnings call?

Q: On the oral VK2735 study, I just wanted to ask if you have a sense of whether the pharmacology of the oral formulation is really translating clinically as you expect, and if the relative potency versus the injectable formulation is sort of holding up? Can you comment on your updated or current conviction there?

Brian: Thanks, Steve. Yeah. We think that, I mean, the mechanism should hold if the drug is well-absorbed and we get good exposures. We're blinded to the study right now. So it's just ongoing.